ULGX Share Price

Open N/A Change Price %
High N/A 1 Day N/A N/A
Low N/A 1 Week N/A N/A
Close N/A 1 Month N/A N/A
Volume N/A 1 Year N/A N/A
52 Week High N/A
52 Week Low N/A
ULGX Important Levels
Resistance 2 N/A
Resistance 1 N/A
Pivot N/A
Support 1 N/A
Support 2 N/A
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Urologix, Inc. (NASDAQ: ULGX)

ULGX Technical Analysis 1
As on N/A ULGX Share Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS.
ULGX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ULGX Other Details
Segment EQ
Market Capital 16210637.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.urologix.com
ULGX Address
ULGX
14405 21st Avenue North
Suite 110
Minneapolis, MN 55447
United States
Phone: 763-475-1400
Fax: 763-404-8118
Interactive Technical Analysis Chart Urologix, Inc. ( ULGX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Urologix, Inc.
ULGX Business Profile
Urologix, Inc. (Urologix) develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the most common prostate problem for men over 50. It markets both the Cooled ThermoTherapy (CTT) product line and the Prostiva Radio Frequency (RF) Therapy System. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. It acquired the worldwide license to the Prostiva RF Therapy System, in September 2011.